On October 21, 2024, Alpha Tau Medical Ltd. announced its acceptance into the FDA’s Total Product Life Cycle Advisory Program to enhance market access for its Alpha DaRT® treatment for recurrent glioblastoma multiforme. This event is considered significant from an equity investor perspective and carries a positive sentiment.